Shared and Unique Effects of Long-Term Administration of Methylphenidate and Atomoxetine on Degree Centrality in Medication-Naïve Children With Attention-Deficit/Hyperactive Disorder

Overview

Journal Int J Neuropsychopharmacol

Publisher Oxford University Press

Specialty Psychiatry

Date 2022 May 7

PMID 35524732

Authors

Zhao Fu

Jing Yuan

Xuyao Pei

Kangfuxi Zhang

Chenyang Xu

Na Hu

Rao Xie

Yilu Zhao

Yufeng Wang

Li Yang

Qingjiu Cao

Affiliations

Soon will be listed here.

Abstract

Background: Although methylphenidate (MPH) and atomoxetine (ATX) can improve clinical symptoms and functional impairments in attention deficit/hyperactive disorder (ADHD), the underlying psychopharmacological mechanisms have not been clearly elucidated. Therefore, we aimed to explore the shared and unique neurologic basis of these 2 medications in alleviating the clinical symptoms and functional impairments observed in ADHD.

Methods: Sixty-seven ADHD and 44 age-matched children with typical development were included and underwent resting-state functional magnetic resonance imaging scans at baseline. Then patients were assigned to MPH, ATX, or untreated subgroups, based on the patients' and their parents' choice, for a 12-week follow-up and underwent a second functional magnetic resonance imaging scan. The treatment effect on degree centrality (DC) was identified and correlated with clinical symptoms and functional impairments in the ADHD group.

Results: Both MPH and ATX normalized the DC value in extensive brain regions mainly involving fronto-cingulo-parieto-cerebellum circuits. However, ATX showed limited significant effects on the cerebellum compared with ADHD at baseline. The improvements in clinical symptoms were correlated with increased DC in the right inferior temporal gyrus in both MPH and ATX subgroups but showed opposite effects. The alleviation of functional impairments in the school/learning domain negatively correlated with decreased DC in the bilateral cerebellum after MPH treatment, and the family functional domain positively correlated with decreased DC in the cerebellum and negatively correlated with decreased DC in the postcentral gyrus after ATX treatment.

Conclusions: Both MPH and ATX can normalize abnormal brain functions that mainly involve the fronto-cingulo-parieto-cerebellum circuit in ADHD. Furthermore, the 2 medications showed shared and unique effects on brain functions to alleviate clinical symptoms and functional impairment.

Citing Articles

Genome data based deep learning identified new genes predicting pharmacological treatment response of attention deficit hyperactivity disorder.

Zhao Y, Fu Z, Barnett E, Wang N, Zhang K, Gao X Transl Psychiatry. 2025; 15(1):46.

PMID: 39920114 PMC: 11806042. DOI: 10.1038/s41398-025-03250-5.

Neuroimaging as a Tool for Advancing Pediatric Psychopharmacology.

Bartkoski M, Tumberger J, Martin L, Choi I, Lee P, Strawn J Paediatr Drugs. 2025; .

PMID: 39899194 DOI: 10.1007/s40272-025-00683-9.

Overlapping and differential neuropharmacological mechanisms of stimulants and nonstimulants for attention-deficit/hyperactivity disorder: a comparative neuroimaging analysis.

Pan N, Ma T, Liu Y, Zhang S, Hu S, Shekara A Psychol Med. 2025; :1-15.

PMID: 39806554 PMC: 11769909. DOI: 10.1017/S003329172400285X.

Functional imaging derived ADHD biotypes based on deep clustering: a study on personalized medication therapy guidance.

Feng A, Zhi D, Feng Y, Jiang R, Fu Z, Xu M EClinicalMedicine. 2025; 77():102876.

PMID: 39763511 PMC: 11701483. DOI: 10.1016/j.eclinm.2024.102876.

Functional Imaging Derived ADHD Biotypes Based on Deep Clustering May Guide Personalized Medication Therapy.

Feng A, Feng Y, Zhi D, Jiang R, Fu Z, Xu M Res Sq. 2023; .

PMID: 37790426 PMC: 10543279. DOI: 10.21203/rs.3.rs-3272441/v1.

References

Kowalczyk O, Cubillo A, Smith A, Barrett N, Giampietro V, Brammer M . Methylphenidate and atomoxetine normalise fronto-parietal underactivation during sustained attention in ADHD adolescents. Eur Neuropsychopharmacol. 2019; 29(10):1102-1116. DOI: 10.1016/j.euroneuro.2019.07.139. View

Friedman L, Rapoport J . Brain development in ADHD. Curr Opin Neurobiol. 2014; 30:106-11. DOI: 10.1016/j.conb.2014.11.007. View

Cortese S . Pharmacologic Treatment of Attention Deficit-Hyperactivity Disorder. N Engl J Med. 2020; 383(11):1050-1056. DOI: 10.1056/NEJMra1917069. View

Yang L, Cao Q, Shuai L, Li H, Chan R, Wang Y . Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial. Int J Neuropsychopharmacol. 2011; 15(1):15-26. DOI: 10.1017/S1461145711001490. View

Zuo X, Ehmke R, Mennes M, Imperati D, Castellanos F, Sporns O . Network centrality in the human functional connectome. Cereb Cortex. 2011; 22(8):1862-75. DOI: 10.1093/cercor/bhr269. View

An L, Cao X, Cao Q, Sun L, Yang L, Zou Q . Methylphenidate normalizes resting-state brain dysfunction in boys with attention deficit hyperactivity disorder. Neuropsychopharmacology. 2013; 38(7):1287-95. PMC: 3656372. DOI: 10.1038/npp.2013.27. View

Yu G, Li G, Markowitz J . Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition. J Child Adolesc Psychopharmacol. 2016; 26(4):314-26. PMC: 4876529. DOI: 10.1089/cap.2015.0137. View

Shaw P, Stringaris A, Nigg J, Leibenluft E . Emotion dysregulation in attention deficit hyperactivity disorder. Am J Psychiatry. 2014; 171(3):276-93. PMC: 4282137. DOI: 10.1176/appi.ajp.2013.13070966. View

Chen X, Lu B, Yan C . Reproducibility of R-fMRI metrics on the impact of different strategies for multiple comparison correction and sample sizes. Hum Brain Mapp. 2017; 39(1):300-318. PMC: 6866539. DOI: 10.1002/hbm.23843. View

10.

Polanczyk G, Willcutt E, Salum G, Kieling C, Rohde L . ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol. 2014; 43(2):434-42. PMC: 4817588. DOI: 10.1093/ije/dyt261. View

11.

Pelham Jr W, Fabiano G, Massetti G . Evidence-based assessment of attention deficit hyperactivity disorder in children and adolescents. J Clin Child Adolesc Psychol. 2005; 34(3):449-76. DOI: 10.1207/s15374424jccp3403_5. View

12.

Frank D, Dewitt M, Hudgens-Haney M, Schaeffer D, Ball B, Schwarz N . Emotion regulation: quantitative meta-analysis of functional activation and deactivation. Neurosci Biobehav Rev. 2014; 45:202-11. DOI: 10.1016/j.neubiorev.2014.06.010. View

13.

Coghill D, Joseph A, Sikirica V, Kosinski M, Bliss C, Huss M . Correlations Between Clinical Trial Outcomes Based on Symptoms, Functional Impairments, and Quality of Life in Children and Adolescents With ADHD. J Atten Disord. 2017; 23(13):1578-1591. PMC: 6732817. DOI: 10.1177/1087054717723984. View

14.

Silk T, Malpas C, Vance A, Bellgrove M . The effect of single-dose methylphenidate on resting-state network functional connectivity in ADHD. Brain Imaging Behav. 2016; 11(5):1422-1431. DOI: 10.1007/s11682-016-9620-8. View

15.

Cubillo A, Smith A, Barrett N, Giampietro V, Brammer M, Simmons A . Shared and drug-specific effects of atomoxetine and methylphenidate on inhibitory brain dysfunction in medication-naive ADHD boys. Cereb Cortex. 2012; 24(1):174-85. PMC: 3862268. DOI: 10.1093/cercor/bhs296. View

16.

Castellanos F, Proal E . Large-scale brain systems in ADHD: beyond the prefrontal-striatal model. Trends Cogn Sci. 2011; 16(1):17-26. PMC: 3272832. DOI: 10.1016/j.tics.2011.11.007. View

17.

Jia X, Wang J, Sun H, Zhang H, Liao W, Wang Z . RESTplus: an improved toolkit for resting-state functional magnetic resonance imaging data processing. Sci Bull (Beijing). 2023; 64(14):953-954. DOI: 10.1016/j.scib.2019.05.008. View

18.

Soman S, Vijayakumar N, Ball G, Hyde C, Silk T . Longitudinal Changes of Resting-State Networks in Children With Attention-Deficit/Hyperactivity Disorder and Typically Developing Children. Biol Psychiatry Cogn Neurosci Neuroimaging. 2022; 8(5):514-521. DOI: 10.1016/j.bpsc.2022.01.001. View

19.

Yan C, Wang X, Zuo X, Zang Y . DPABI: Data Processing & Analysis for (Resting-State) Brain Imaging. Neuroinformatics. 2016; 14(3):339-51. DOI: 10.1007/s12021-016-9299-4. View

20.

Coghill D, Seth S, Matthews K . A comprehensive assessment of memory, delay aversion, timing, inhibition, decision making and variability in attention deficit hyperactivity disorder: advancing beyond the three-pathway models. Psychol Med. 2013; 44(9):1989-2001. DOI: 10.1017/S0033291713002547. View